Related Experiment Video

Updated: Aug 7, 2026

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
11:32

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry

Published on: September 28, 2016

Antiarrhythmic drugs and cardiac ion channels: mechanisms of action

E Carmeliet1, K Mubagwa

  • 1Centre for Experimental Surgery and Anaesthesiology, University of Leuven, Belgium. Edward.Carmeliet@med.kuleuven.ac.be

Progress in Biophysics and Molecular Biology
|October 24, 1998
PubMed

Insights

This review analyzes how antiarrhythmic drugs interact with ion channels and receptors to modify critical electrophysiological properties, aiming to prevent or treat arrhythmias effectively.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cardiology

Background:

  • Arrhythmias arise from disruptions in electrophysiological properties.
  • Antiarrhythmic drugs target molecular components like ion channels and receptors.
  • Understanding drug-target interactions is crucial for effective arrhythmia management.

Purpose of the Study:

  • To analyze the interaction between antiarrhythmic drugs and their molecular targets (ion channels and receptors).
  • To explore how these interactions modify the "vulnerable parameter" crucial for arrhythmia genesis.
  • To evaluate if current antiarrhythmic drugs effectively alter this parameter to prevent or treat arrhythmias.

Main Methods:

  • Review of general principles of drug-channel interactions, including state-dependent binding.
  • Analysis of the modulated-receptor hypothesis in drug-channel interactions.
  • Systematic description of drug interactions with specific ion channels (Na+, Ca2+, K+, "pacemaker") and receptors.

Main Results:

  • Drug binding to ion channels is state-dependent (rested, activated, inactivated states).
  • Drug interactions can result in either inhibition or stimulation of channel activity.
  • Specific state-dependent blocks and changes in channel kinetics influence ionic currents, affecting voltage and frequency dependence.

Conclusions:

  • Antiarrhythmic drugs interact with ion channels and receptors in a state-dependent manner.
  • The modulation of the "vulnerable parameter" by these drugs is key to their antiarrhythmic effects.
  • Further evaluation is needed to confirm if existing drugs optimally modify the vulnerable parameter for arrhythmia control.

More Related Videos

Isolation of Atrial Myocytes from Adult Mice08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...